Stockreport

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates [Yahoo! Finance]

Arcellx, Inc.  (ACLX) 
PDF -- The global Phase 3 trial, iMMagine-3, has been initiated by Kite -- -- U.S. FDA clears anito-cel IND application for myasthenia gravis, an autoimmune disease -- [Read more]